Relugolix in Monotherapy and Combined Therapy for the Treatment of Uterine Diseases and Its Effects on Bones: A Systematic Review.
Background: Uterine fibroids (UFs) and endometriosis are gynecological conditions that significantly increase morbidity among women of reproductive age. Relugolix, a novel gonadotropin-releasing hormone receptor antagonist, is approved in combined therapy …
Optimizing endometriosis diagnosis and mapping: The important role of advanced transvaginal ultrasound.
Endometriosis is estimated to affect 5%-10% of women of reproductive age, making timely diagnosis essential for initiating treatment, alleviating symptoms, and reducing the risk of disease progression. Unfortunately, the diagnostic …